ClinicalTrials.gg
RecruitingNCT07619885Updated Jun 29, 2026

The Pharmacokinetics and Pharmacodynamics Study of Evategrel CG-0255 Besylate)and Plavix® in Healthy Participants

A Phase 1 interventional study of CG-0255 Besylate for Injection and CG-0255 Besylate Capsule in Acute Coronary Syndromes (ACS), Recent Myocardial Infarction and Recent Stroke, sponsored by Shanghai CureGene Pharmaceutical Co., Ltd.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Shanghai CureGene Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 265 studies in Acute Coronary Syndrome with a site in United States — 14 open to participants now, 21 under way, 2 of them phase 3. Acute Coronary Syndrome · United States.

Planned enrollment
97th of 186
136 · median 150
Started
2026
with 3 others
Phase 1
10 of 265
1 open now
Primary completion
2026-10
later than 8 of 20 live
Registered
264th of 265
by date

Among the 265 studies in Acute Coronary Syndrome with a site in United States, this one is the 97th largest by planned enrollment of the 186 interventional ones that give a count, is one of 4 that started in 2026, is one of 10 in phase 1, reaches primary completion later than 8 of the 20 other live ones, and was the 264th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

14 of the 265 studies in Acute Coronary Syndrome with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Acute Coronary Syndrome with a site in United States, or all of them as a file.
02

Study summary

CG-0255 is a novel investigational prodrug of the active metabolite of Plavix®, but with different active metabolite conversion routes. This is a randomized, open-label and Plavix®-controlled study to compare the PK and PD of CG-0255 Besylate and Plavix® in healthy participants.

03

Conditions studied

  • Acute Coronary Syndromes (ACS)
  • Recent Myocardial Infarction
  • Recent Stroke
  • Peripheral Arterial Disease
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be fully informed about the study, willing to participate, and sign the document prior to any procedure.
  • Healthy male and female participants, aged 18 to 55 years (inclusive) at time of signing informed consent form.
  • (BMI) between 18 and 32 kg/m2 (inclusive) at screening and body weight between 45 and 120 kg (inclusive).
  • Smoking \< 10 cigarettes (10-20 mg of nicotine/month) or equivalent amount of nicotine products per month within 6 months prior to screening and agree to abstain from tobacco and/or nicotine products during the study.
  • Generally normal health, or abnormalities deemed non- by the Investigator or designee based on medical history, physical examination, vital signs, 12-lead , and clinical laboratory tests at the screening and at the admission.
  • For female participants,

    1. Woman of (WOCBP) must be non-pregnant and non-lactating, and must agree to use highly effective methods and abstain from egg collection or donation from the screening period to 3 months after the last dose of the study treatment (CG-0255 Besylate or Plavix®). The male partner of a female participant also needs to use condoms during this period.
    2. Woman of non-childbearing potential (WONCBP) must be post menopausal (spontaneous amenorrhea for at least 12 consecutive months prior to dosing) with confirmation by documented FSH levels ≥40 mIU/mL; or surgically sterile (bilateral oophorectomy, bilateral salpingectomy, hysterectomy, or bilateral tubal ligation) at least 3 months prior to dosing.
  • Male participants considered fertile must agree to not plan to father a child, not donate sperm and take effective contraceptive methods from the screening period to 3 months after the last dose of the study treatment. The female partner of a male participant also needs to use a highly effective contraceptive method during this period.
  • Male participants (including men who have had a vasectomy) with a pregnant partner must agree to use a condom from the screening period to 3 months after the last dose of the study treatment.
  • Participants must be able to communicate well with the Investigator or designee, as well as understand and adhere to the study's requirements.

Exclusion criteria

Exclusion Criteria:

  • Difficulty with venous blood collection or a history of fainting upon seeing blood or needles.
  • drug intolerance or allergy or known or suspected to any component of CG-0255 Besylate or Plavix®, or other related drugs.
  • Participation in a clinical research study involving the administration of an or marketed drug or device within 30 days (or 5 times half-life, whichever is longer) prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days (or 5 times half-life, whichever is longer) prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration.
  • Current or unresolved digestive tract diseases (dyspepsia, gastroesophageal reflux, gastro-hemorrhage, or digestive tract ulcer disease) within the past 6 months, or frequent (> 1 time/week) digestive tract symptoms including dysphagia, abdominal pain, abdominal distension, acid regurgitation, belching, hematemesis, bloody stool, anorexia, nausea, heartburn, and other symptoms that may increase the risk of bleeding, as determined by the Investigator or designee.
  • Any clinically significant diseases including but not limited to pulmonary, cardiovascular, gastrointestinal, hematological, endocrinological, immunological, dermatological, malignant diseases, mental and nervous systems, and other related diseases or any other condition at the discretion of the Investigator or designee.
  • History of previous or current active bleeding (such as intracranial hemorrhage, gastrointestinal hemorrhage, urethral hemorrhage, hemoptysis, vitreous hemorrhage, bleeding caused by stool and hemorrhoids), or stroke, abnormal bleeding (such as prolonged bleeding time after tooth extraction), presence of petechiae and/or ecchymosis on physical examination, or suspected vascular malformations (such as aneurysms or early-onset stroke, not exceeding the age limit specified in the inclusion criteria).
  • \<120 g/L for males and \<110 g/L for females at screening.
  • Medication history of NSAIDs (including Aspirin) or other drugs that may affect coagulation function (e.g, oral anticoagulants) within 4 weeks before the screening.
  • count \< 120 × 10\^9/L at screening.
  • Laboratory measures with values above the 1.5 × (ULN) and deemed clinically significant by the Investigator or designee for the (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST).
  • Clinically significant abnormalities ( interval ≥ 450 ms for male, ≥ 470 ms for female (Fridericia's Correction)) or vital signs abnormalities (systolic BP lower than 90 or over 140 mmHg, diastolic BP lower than 50 or over 90mmHg, HR less than 50 or over 100 bpm, or RR less than 10 or over 22 bpm) at screening.
  • Major surgery within 3 months prior to the first dose of study treatment or plans for surgery during the study.
  • Use of prescription, nonprescription or dietary supplements (e.g. food supplements and herbal supplements) within 14 days or 5 times the half life (whichever is longer) prior to the first dose of study treatment (excluding drug products without significant systemic absorption at the discretion of the Investigator or designee), or depot injection or implant within 3 months prior to first dosing, with the exception of the occasional use of acetaminophen (up to 2 g daily).
  • Vaccinated within 14 days prior to the first dose of study treatment or planned to be vaccinated during the study.
  • Consuming quinine containing products, including quinine water, tonic water bitter lemon, jello shots, any quinine preparations or Cinchona tree bark reparations (e.g., herbal medications containing Cinchona tree bark), and grapefruit or products containing grapefruit, or participants have engaged strenuous exercise or any other factors affecting drug absorption, distribution, metabolism and excretion within 7 days before the first dose of study treatment.
  • History of drug abuse within 1 year before screening, or recreational use of soft drugs (such as marijuana) within 1 month or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 3 months prior to screening.
  • Positive urine drug screen, urine cotinine test, or alcohol breath test at screening or at the admission.
  • Positive pregnancy test or lactating female participant at screening or at the admission.
  • Donation of plasma within 7 days prior to the first dosing or donation or loss of 500 mL or more of whole blood within 8 weeks prior to the first dosing.
  • History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 10 units for women or 15 units for men of alcohol per week (1 unit = 340 mL of beer 5%, 140 mL of wine 12%, or 45 mL of distilled alcohol 40%).
  • Known hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.
  • Excessive drinking of tea, coffee, or caffeine-containing beverage (>600 mg/day) within 30 days before screening; intake of caffeine- or xanthine rich foods or drinks (e.g., coffee, tea, chocolate, cola drinks) within 48 hours prior to the first dose of study treatment, which may metabolize into caffeine or xanthine.
  • Positive screening for (HIV) antigen and antibody, surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or virus (HCV) antibody at screening.
  • Estimated (eGFR) \<60 mL/min as calculated per CKD-EPI equation, at screening.
  • Use of any drugs known to induce or inhibit hepatic drug metabolism (including CYP2C19 inducers or inhibitors) within 30 days prior to the first study drug administration or 5 half-lives (whichever is longer) until the end of the study.
  • Participants deemed ineligible to participate in this study by the Investigator or designee.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
136 participants (estimated)

Study arms

  • Experimental
    Treatment A: CG-0255 oral for both Loading Dose (LD) and Maintenance Dose (MD)

    For Treatment A, participants will be administered with 3 mg CG-0255 Besylate capsules on Day 1. Subsequently, they will receive 0.75 mg CG-0255 Besylate capsules once daily from Days 2 to 7.

    Drug: CG-0255 Besylate Capsule

  • Experimental
    Treatment B: CG-0255 iv for LD and oral for MD

    For Treatment B, participants will be administered with 0.05 mg/kg CG-0255 Besylate for IV infusion within 30 minutes on Day 1. Subsequently, they will receive 0.75 mg CG-0255 Besylate capsules once daily from Days 2 to 7.

    Drug: CG-0255 Besylate for Injection · Drug: CG-0255 Besylate Capsule

  • Active comparator
    Treatment C: Plavix® 300mg for LD and 75mg for MD

    For Treatment C, participants will be administered with 300 mg Plavix® on Day 1 as 4 x 75 mg Plavix® tablets. Subsequently, they will receive 75 mg Plavix® once daily from Days 2 to 7.

    Drug: Clopidogrel

  • Active comparator
    Treatment D: Plavix® 600mg for LD and 75mg for MD

    For Treatment D, participants will be administered with 600 mg Plavix® on Day 1 as 8 x 75 mg Plavix® tablets. Subsequently, they will receive 75 mg Plavix® once daily from Days 2 to 7.

    Drug: Clopidogrel

Interventions

  • DrugCG-0255 Besylate for Injection

    Calculate the dosage and number of vials required for a participant according to body weight. Reconstitute with 5 mL of sterile water for each 5 mg/vial to get clear solution for injection in 1 mg/mL (as CG-0255). The reconstituted CG-0255 Besylate for injection (1 mg/mL), must be further diluted in 100 mL normal saline infusion bag, following the instruction in the pharmacy manual.

  • DrugCG-0255 Besylate Capsule

    Orally administered as LD or MD with approximately 240 mL of water.

  • Orally administered as LD or MD with approximately 240 mL of water.

06

What researchers measure

Primary outcomes

  1. To compare the PK of the active metabolite CG-0236 of CG-0255 Besylate and of Plavix® when they are administered as loading dose (LD) and maintenance dose (MD) in healthy participants.

    Area under the plasma concentration-time curve from time 0 to the last quantifiable measurement time-point (AUClast)

    Time frame: Day 1 (LD) and Day 7 (MD)

  2. To compare the PK of the active metabolite CG-0236 of CG-0255 Besylate and of Plavix® when they are administered as loading dose (LD) and maintenance dose (MD) in healthy participants.

    Peak Plasma Concentration (Cmax)

    Time frame: Day 1 (LD) and Day 7 (MD)

Secondary outcomes

  1. To compare the PD of the active metabolite CG-0236 of CG-0255 Besylate and of Plavix® when administered as LD and MD in healthy participants.

    The inhibition of platelet reactivity unit (PRU) based on VerifyNow assay, the inhibition of maximum platelet aggregation (MPA) based on Light Transmittance Aggregometry (LTA) assay.

    Time frame: Day 1 (LD) and Day 7 (MD)

  2. To evaluate the Cmax of CG-0255 when administered CG-0255 Besylate as LD and MD in healthy participants.

    Peak Plasma Concentration (Cmax)

    Time frame: Day 1 (LD) and Day 7 (MD)

  3. To evaluate the safety and tolerability of CG-0255 Besylate and Plavix® when administered as LD and MD in healthy participants.

    Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment.

    Time frame: Day 1-13

  4. To evaluate the AUC of CG-0255 when administered CG-0255 Besylate as LD and MD in healthy participants.

    Area under the plasma concentration-time curve from time 0 to the last quantifiable measurement time-point (AUClast)

    Time frame: Day 1 (LD) and Day 7 (MD)

Other outcomes

  1. To explore the effect of CYP2C19 genetic polymorphism on the PK of CG-0236 following CG-0255 Besylate and Plavix® administration.

    Comparisons of plasma AUC of CG-0236 stratified by CYP2C19 genotypes: normal, intermediate and poor metabolizers

    Time frame: Day 1 (LD) and Day 7 (MD)

  2. To explore the effect of CYP2C19 genetic polymorphism on the PD following CG-0255 Besylate and Plavix® administration.

    Comparison of platelet reactivity unit (PRU) and/or maximal platelet aggregation (MPA) inhibition stratified by CYP2C19 genotypes: normal, intermediate and poor metabolizers.

    Time frame: Day 1 (LD) and Day 7 (MD)

  3. To explore the effect of CYP2C19 genetic polymorphism on the PK of CG-0236 following CG-0255 Besylate and Plavix® administration.

    Comparisons of plasma Cmax of CG-0236 stratified by CYP2C19 genotypes: normal, intermediate and poor metabolizers.

    Time frame: Day 1 (LD) and Day 7 (MD)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Oct 2026, 4 months later.

Of 16 phase 1 interventional studies under Acute Coronary Syndrome, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 14. This study's planned 4 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
Jun 2, 2026
StartEst.
Jun 2026
Primary completionEst.
Oct 2026
CompletionEst.
Dec 2026
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07619885
Lead sponsor
Shanghai CureGene Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
Jun 2026 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 29, 2026

Study contacts

Isabel Pino
Contact
Isabel.pino@syneoshealth.com
305-547-5813

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion